Cognetivity Neurosciences Ltd
CNSX:CGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cognetivity Neurosciences Ltd
CNSX:CGN
|
CA |
|
L
|
LiveWire Group Inc
F:P9N
|
US |
|
10X Genomics Inc
NASDAQ:TXG
|
US |
|
T
|
Tony G Co-Investment Holdings Ltd
CNSX:TONY
|
CA |
|
CeoTronics Audio Video Data Communication AG
XETRA:CEK
|
DE |
|
Soc Centrale Bois Scieries Manche SA
PAR:CBSM
|
FR |
|
L
|
Lion Rock Resources Inc
XTSX:ROAR
|
CA |
|
Yijiahe Technology Co Ltd
SSE:603666
|
CN |
|
B
|
Brim hf
ICEX:BRIM
|
IS |
Cognetivity Neurosciences Ltd
Cognetivity Neurosciences Ltd. operates as a technology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-03-19. The firm is engaged in developing a cognitive testing platform, the integrated cognitive assessment (ICA), for use in medical and commercial environments for allowing early diagnosis of dementia. The Company’s ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from early detection of cognitive impairment in dementia and multiple sclerosis (MS), to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The firm serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.
Cognetivity Neurosciences Ltd. operates as a technology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-03-19. The firm is engaged in developing a cognitive testing platform, the integrated cognitive assessment (ICA), for use in medical and commercial environments for allowing early diagnosis of dementia. The Company’s ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from early detection of cognitive impairment in dementia and multiple sclerosis (MS), to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The firm serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.
